Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05690646

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

Conditions: Cardiac Surgery

Sex: All
Ages: 18 Years – N/A
Phase: PHASE4
Enrollment: 436
Sponsor: China National Center for Cardiovascular Diseases

Location: China

Summary

Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery during covid-19 pandemics (the pep trial) is a multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications after cardiac surgery.

Eligibility Criteria

Inclusion Criteria:Age ≥18 yearsCOVID-19 nucleic acid test or antigen test positive history, without symptom or recover from COVID-19 related symptoms ≥2 weeksReceive open-chest cardiac surgeryCOVID-19 nucleic acid test and antigen test negative and no signs of pneumonia in chest CTPatients with written informed consent.Exclusion Criteria:Emergency surgeryeGFR ≤30ml/minSevere liver dysfunctionContraindication to nirmatrelvir/ritonavir or ursodeoxycholic acid

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05690646). StuddyBuddy aggregates publicly available trial information.